Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

324.66 Billion KRW

Sector

Healthcare

Website

https://www.ilyang.co.kr

Description

Ilyang Pharmaceutical Co.

Read More

Overview

Value

49

Growth

35

Health

43

Management

2

Analyst Opinion

86

Total

43

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Price-to-earnings ratio of 12.9 is lower than the market average (19.6x)
  • Has a margin-of-safety above fair value
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings have declined recently
  • There is a history of diluting shareholders
  • Does not hold enough liquid assets to cover short term liabilities
  • Poor earnings and cashflow growth
  • 0

Market Peers

007570.KS

Key Figures

PE Ratio (TTM)

12.93

Margin Of Safety (DCF)

83.22%

Revenue Growth (5 Year Average)

-0.20%

Ratings Consensus

Strong Buy

Share Buybacks

-0.01%

Dividend Yeild (TTM)

1.22%

Valuation

Value Score

49

  • Price-to-earnings ratio of 12.9 is lower than the market average (19.6x)
  • Margin-of-safety of 83.22% is better than the market average (17.95%)
  • Estimated intrinsic-value of 32.61 Thousand KRW is higher than current price ( 17.95 Thousand KRW)
  • Free-cashflow-yeild of 2.92% is worse than the market average (4.7%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 26919.2 KRW

Current Price: 17800 KRW

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

12.93x

Free Cashflow Yeild

2.92%

PE/Earnings Growth

N/A

Price/Book

1.26x

Growth

Growth Score

35

  • Revenue growth has improved this yeara
  • 5 Year Average Cashflow growth of 24.73% is higher than the market average (12.35%)
  • 5 Year Average Revenue growth of -0.20% is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of -8.21% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • Free Cashflow growth has slowed this year

Revenue Growth

-0.20%

Earnings Growth

-8.21%

Cashflow Growth

24.73%

Health

Health Score

43

  • Has a low level of debt
  • Normal operation does not require debt to be sustainable
  • Assets do not cover liabilities
  • Debt repayments significantly impact cashflow

Altman Z Score

2.09

Piostroski Score

8.00

Debt/Equity

0.37x

Current Assets/Liabilities

0.66x

Free Cashflow/Total Debt

0.11x

Debt/Capital

0.67x

Management

Management Score

2

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of 1.81% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Has returned higher dividends when earnings have fallen
  • Return-on-equity of 1.43% is lower than the market average (15%)

Average Buybacks/Dilution

-0.01%

Recent Buybacks/Dilution

-0.63%

5 Year Price Volitility

46.25%

Return On Assets

0.67%

Return On Capital Employed

1.81%

Return On Equity

1.43%

Return On Free Cashflow

-399.46%

Return On Investments

113.75%

Analysts

Analyst Opinion

86

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Ilyang Pharmaceutical Co.,Ltd

Currency

KRW

Beta

0.00895

Vol Avg

154841

Ceo

Cik

Cusip

Exchange

KSE

Full Time Employees

675

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

2000-01-04

Address

110, Hagal-ro

City

Yongin

State

Country

US

Zip

17096

Phone

82 3 1281 7851

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies